Ivabradine Doc Generici

Ivabradine, the active ingredient in Ivabradine Doc Generici, is an If channel inhibitor presented as an oral tablet for oral use. It is indicated for chronic stable angina pectoris and heart failure with reduced ejection fraction in appropriate patients.

GNH USA supplies Ivabradine Doc Generici as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine is employed in cardiovascular conditions where heart‑rate reduction improves outcomes.

Chronic stable angina pectoris: decreases frequency of angina attacks and improves exercise tolerance. Heart failure with reduced ejection fraction: lowers heart rate, enhancing functional capacity and reducing hospitalisations.

Adverse reactions may occur with ivabradine therapy.

Common Side Effects: - Visual disturbances (phosphenes or luminous phenomena) - Bradycardia - Headache - Dizziness - Fatigue - Blurred vision

Serious or Rare Side Effects: - Severe bradycardia requiring medical intervention - Atrial fibrillation or other arrhythmias - Symptomatic hypotension - Persistent visual loss - Hepatic dysfunction - Allergic reactions such as rash or angioedema

Before initiating ivabradine, consider the following precautions.

Cardiac monitoring: assess resting heart rate and ECG prior to therapy and periodically thereafter. Concomitant bradycardic agents: avoid excessive heart‑rate reduction when used with beta‑blockers or digoxin. Severe hepatic impairment: use with caution; dose adjustment may be required. Pregnancy and lactation: safety not established; avoid unless benefit outweighs potential risk. Drug interactions: review concomitant CYP3A4 inhibitors or inducers. Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Ivabradine may interact with several medicines; awareness helps prevent adverse events.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) – may increase ivabradine exposure. - Other agents that markedly lower heart rate (e.g., beta‑blockers, digoxin) – risk of severe bradycardia. - Concomitant use with other If‑channel inhibitors – additive effect on heart‑rate reduction.

Moderate Interactions (Monitor Closely):\n- Moderate CYP3A4 inhibitors (e.g., erythromycin) – may modestly raise plasma levels. - CYP3A4 inducers (e.g., rifampicin, carbamazepine) – may reduce efficacy. - Diuretics or antihypertensives – monitor blood pressure and electrolytes.